natgillin/translations-raw huggingface dataset:
The method of claim 1, wherein the chelator is found at a final concentration of at least 0.01 M. 
Reagens prema zahtjevu 1, naznačen time da se kelator nalazi u konačnoj koncentraciji od barem 0.01 M.
the cutting of the plate into section bar strips constituting half shells (1, 1') such that by coupling together two half shells (1, 1') so to form the cells, a reduced axial height (p) is obtained of the cells, preferably at most substantially equal to the maximum diameter (1) of the cells; 
rezanje ploče na pojedinačne trake koje predstavljaju polu-okvire (1, 1') tako da međusobnim spajanjem dvaju polu-okvira (1,1') nastaju ćelije na način da se dobiju ćelije smanjene aksijalne visine (p), poželjno najviše u biti da ona bude jednaka maksimalnom promjeru (1) ćelija;
(a') providing a mixture comprising a derivative of telmisartan, an acid and a solvent, wherein the derivative of telmisartan is cyanotelmisartan or carboxamidotelmisartan and the acid is H2SO4, 
(a) pripravi smjese koja sadrži derivat telmisartana, kiselinu i otapalo, gdje je derivat telmisartana cijanotelmisartan ili karboksamidotelmisartan, a kiselina je HSO,,
The method of claim 24 or 25, wherein the effective amount comprises a dose of anti-human PD-1 antibody selected from the group consisting of about 1.0, 3.0, and 10 mg/kg. 
Tekuća farmaceutska formulacija za upotrebu prema patentnom zahtjevu 8, naznačena time što je doza izabrana od 1.0, 3.0 i 10 mg/kg primjenjivana u intervalima od 14 dana ili 21 dana tokom trajanja tretmana.
said flavouring agent comprises: 
navedeno sredstvo za aromatiziranje sadrži:
in the VL sequence: at position 7 a residue S, at position 9 a residue S, at position 11 a residue L, at position 12 a residue P, at position 18 a residue P, at position 47 a residue Q, at position 50 a residue K, at position 68 a residue S, at position 73 a residue G or a residue E, preferably a residue E, at position 82 a residue R, at position 85 a residue A, at position 90 a residue T. 
u VL sekvenci: na položaju 7 ostatak S, na položaju 9 ostatak S, na položaju 11 ostatak L, na položaju 12 ostatak P, na položaju 18 ostatak P, na položaju 47 ostatak Q, na položaju 50 ostatak K, na položaju 68 ostatak S, na položaju 73 ostatak G ili ostatak E, poželjno ostatak E, na položaju 82 ostatak R, na položaju 85 ostatak A, na položaju 90 ostatak T.
A method for selecting a G-protein coupled receptor (GPCR) with increased stability, the method comprising 
Metoda za odabir receptora vezanog na G-proteine (GPCR) s većom konformacijskom stabilnosti, metoda naznačena time da obuhvaća
with the proviso that at least one of R2 and R3 denotes H or is linked via a carbon atom, R4 and R5 independently of one another represent H; CH2F; CHF2; CF3; a C1-4-aliphatic residue, wherein the C1-4 aliphatic residue may be unsubstituted or mono- or polysubstituted; or a C3-6-cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted; 
Cia-alifatski ostatak, pri čemu C,., alifatski ostatak može biti nesupstituiran ili mono- ili polisupstituiran; ili C3_cikloalifatski ostatak ili 3 do 6 član heterocikloalifatski ostatak, svaki puta nesupstituiran ili mono- ili polisupstituiran; pod uvjetom da ako R* i/ili R* označava(ju) 3 do 6 člani heterocikloalifatski ostatak, 3 do 6 člani heterocikloalifatski ostatak je vezan preko ugljikovog atoma, ili
The surface covering according to claim 1 or 2, wherein the particles comprise a coating of silver, aluminum, copper, nickel, gold or an alloy thereof with another metals. 
Podna obloga sukladno patentnim zahtjevima 1 ili 2, naznačena time, da čestice sadrže sloj srebra, aluminija, bakra, nikla, zlata ili njihove legure s drugim metalima.
A compound or pharmaceutically acceptable salt thereof selected from the group consisting of: 
Spoj Formule (I), ili njegova farmaceutski prihvatljiva sol: pri čemu:
In one embodiment of the invention said sample taken is directly measured without any further sample preparation. In one embodiment of the invention said method is performed on a fully automated device. Roche Elecsys®, Abbott Architect®, Siemens Centauer®, Brahms Kryptor®, Biomerieux Vidas®, Alere Triage®. 
Postupak postterapijske kontrole in vitro kod pacijenata sa sepsom u skladu s patentnim zahtjevom 12, naznačen time što je navedeni uzeti uzorak izmjeren izravno, bez ikakve dodatne priprave uzorka. Postupak postterapijske kontrole in vitro kod pacijenata sa sepsom u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što se navedeni postupak provodi posve automatiziranim uređajem.
A compound represented by formula: 
Spoj prikazan formulom O
The identity document (1) according to claim 1, wherein the more than two images are overlapped with respect to each other in such a way that the angle of observation of different images is 6° to 15°. 
Identifikacijski dokument (1) prema bilo kojem od prethodnih zahtjeva, gdje su slike preklopljene jedna u odnosu na drugu na takav način da je kut promatranja različitih slika oko od 6? do 15".
The process of clause 57, wherein step (c) further comprises filtering the reaction mixture to provide a filtrate comprising the compound of formula (VIII). 
Postupak prema patentnom zahtjevu 38, gdje korak (c) dalje sadrži filtriranje reakcijske smjese da bi se dobio filtrat koji sadrži spoj formule (VIII).
removing the ester protecting group R2'. Use of the compounds of formula I in the solid phase peptide synthesis of peptides which comprise a Glu-fatty alkyl side chain building block attached to a Lys-part of the peptide chain. 
Uporaba spojeva formule I prema zahtjevu 1, naznačena time, da se koriste u peptidnoj sintezi krute faze peptida koji sadrže gradivnu komponentu glukoza-masnog alkilnog bočnog lanca pričvršćenog na lizinski nastavak peptidnog lanca.
The method of claim 15, wherein the antibody is administered in combination with chemotherapy or radiation therapy. A composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier. 
Protutijelo ili pripravak za uporabu prema zahtjevu 18 ili 19, naznačen/o time, da se protutijelo ili pripravak daje u kombinaciji s kemoterapijom ili terapijom zračenjem.
Process of claim 1 wherein, the ester protecting group is selected from C1-4-alkyl, optionally substituted with phenyl, C2-4-alkenyl, piperidinyl or dimethylaminoboranyl. 
Postupak prema patentnom zahtjevu 1, naznačen time, da je zaštitna skupina za ester odabrana iz skupine koju čini C1-4-alkil koji se može po izboru supstituirati sa supstituentima iz skupine koju čine fenil, C2-4-alkenil, piperidinil ili dimetilaminoboranil.
The compound or salt according to claim 3, wherein R1 is a morpholino group optionally substituted by C1-6 alkyl group(s), a di(C1-6 alkyl)amino group, a C1-6 alkoxy group or a C3-6 cycloalkyl group. 
Spoj ili sol prema zahtjevu 3, naznačen time, da R' je morfolino-skupina opcijski supstituirana s jednom ili više C1.4 alkil-skupina, di(C;.4 alkil)amino-skupina, C,_4 alkoksi-skupina ili C34 cikloalkil-skupina. HR P20140589 T1
The process of claim 6, which further comprises a step of applying a parting agent to said casting surface before said at least one belt (12, 14) is advanced through the casting cavity (22). 
Postupak prema zahtjevu 6, naznačen time da nadalje sadrži korak nanošenja sredstva za razdvajanje na navedenu površinu lijevanja prije nego što je navedeni barem jedan remen (12, 14) pomaknut unaprijed kroz šupljinu za lijevanje (22).
A compound of claims 21, 22, 23 or 24, wherein ring vertex b is N. 
Spoj u skladu s patentnim zahtjevom 21, 22, 23 ili 24, naznačen time, da je vrh prstena a N.
The fish farming plant of claim 1, further comprising: a first means for providing water flow in the first end section and a second means for providing water flow in the second end section. 
Postrojenje za uzgoj ribe (1) prema zahtjevu 3, naznačeno time da dodatno sadrži: prvo sredstvo za osiguranje strujanja vode u prvom kraju i a drugo sredstvo za osiguranje strujanja vode u drugom kraju odjeljka.
In a preferred embodiment of the method according to the invention the magnetic particles are applied in the form of a liquid suspension, in particular in the form of an aqueous suspension, onto the cysts, preferably when the cysts have a dry surface so that they are free flowing. 
Postupak prema zahtjevu 1, naznačen time što se magnetske čestice na ciste primjenjuju u obliku tekuće suspenzije, točnije u obliku vodene suspenzije, poželjno kada ciste imaju suhu površinu tako da se slobodno kreću.
about 0.5% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 70.5% metformin hydrochloride; about 8% hydroxypropyl cellulose; about 12.5% microcrystalline cellulose; about 8% sodium starch glycolate; and about 0.6% magnesium stearate; 
(A) 0.5% dapagliflozina ili dapagliflozin (S) propilen glikol hidrata; 70.5% metformin hidroklorida; 8% hidroksipropil celuloze; 12.5% mikrokristalne celuloze; 8% natrijevog škrob glikolata; i 0.6% magnezijevog stearata;
In one form, the utility connectors are of a blind mate, quick connect type and are slidably enagageable with mating connectors. 
U jednoj izvedbi priključci su klizni, omugućuje brzo priključivanje i spajaju se s odgovarajućim utikačima pomoću kliznog kontakta.
The test compounds (diacids, compounds 1A to 12A and TLK117) were dissolved in dimethyl sulfoxide (DMSO) and diluted with DMSO to the appropriate concentration for the assay (8 concentrations over range with midpoint near expected IC50). 
Testirani spojevi (dikiseline, spojevi 1A do 12A i TLK 117) otopljeni su u dimetil sulfoksidu (DMSO) i razrijeđeni sa DMSO do prikladne koncentracije za pokus (8 koncentracija preko raspona sa središnjom točkom blizu očekivane IC50- koncentracija koja uzrokuje 50% inhibicije aktiviteta enzima).
The compounds of this invention can be made by various methods known in the art including those of the following schemes and in the specific embodiments section. 
Spojevi prema ovom izumu se mogu pripremiti pomoću različitih postupaka koji su poznati u tehnici uključujući ono iz sljedećih shema i dijela s posebnim varijantama.
dissolving epidaunorubicin hydrochloride in a solvent mixture I comprising (i) solvent A and (ii) solvent B or C, and 
Otapanje 4'-epidaunorubicin-hidroklorida u mješavini otapala I, koja sadrži otapalo A (i) i otapalo B (ii) ili C i
These results are considered predictive of efficacy in the therapeutic methods of the third aspect of this invention, because TLK199 (the diethyl ester of TLK117 tested in these assays) has shown myelostimulant activity in humans and chemopotentiation activity in an animal model. 
Ovi rezultati su razmatrani po predviđenoj učinkovitosti u terapijskim metodama trećeg aspekta ovog izuma, budući je TLK 199 (dietil ester od TLK 117 testiran u ovim pokusima) pokazao mielostimulativni aktivitet kod ljudi 1 kemopojačani aktivitet na životinjskom modelu.
This formulation is unstable with long-term storage at refrigerated and room temperature, and should therefore be stored between −15 and −25° C., protected from light. 
Ovaj oblik je nestabilan pri dugotrajnom čuvanju u hladnjaku i na sobnoj temperaturi, i trebalo bi ga prema tome čuvati između -15 i -25%C, zaštićenog od svjetlosti.
The composition or vaccine for use according to any one of claims 1-9 or the vector for use according to claim 11, further wherein said composition, vaccine or vector is for use in a method of vaccinating an animal, the method comprising at least one administration of the composition, vaccine or vector. 
Sastav ili cjepivo za uporabu prema bilo kojem od zahtjeva 1-9, ili vektor za uporabu prema zahtjevu 11, nadalje naznačeni time, da se navedeni sastav ili vektor, ili navedeno cjepivo, upotrebljavaju u postupku cijepljenja HR P20190525 T1 životinje, pri čemu postupak obuhvaća najmanje jednu primjenu sastava, cjepiva ili vektora.
Results are expressed as percentage of inhibition respect to control in the absence of compounds). 
Rezulti su prikazani kao postotak inhibicije u odnosu na kontrolu (u odsutnosti spojeva).
Filling up the engraving renders the engraved plate a smooth surface again, which is of advantage during the printing and magnetic image transfer operations. 
Ispunjavanjem gravure ponovo se dobiva glatka površina na graviranoj ploči, što predstavlja prednost tijekom operacija tiskanja 1 prijenosa magnetskih slika.
The retinal derivative for use according to claim 2, which is a 9-cis-retinyl ester of a C3 to C22 polycarboxylate. 
Derivat retinala za upotrebu u skladu s patentnim zahtjevom 2, naznačen time, da je to 9-cis-retinil ester C3-Cx2 polikarboksilata,
Transforms from monoclinic to cubic phase at 600-2200° C. with a volume expansion of 10%. 
Transformacija iz monoklinske u kubičnu fazu pri 600-2200 "C s ekspanzijom volumena od 10%.
187 30 Vaccine comprising at least two fragments of Proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein a first fragment of said at least two fragments comprises at least 9 consecutive amino acid residues of amino acid residues 153 to 165 of PCSK9 according to SEQ ID No. 9 and a second fragment of said at least two fragments comprises at least 9 consecutive amino acid residues of amino acid residues 209 to 222 of PCSK9 according to SEQ ID No. 9. 
Cjepivo, naznačeno time, da obuhvaća najmanje dva fragmenta proproteinske konvertaze subtilizin/keksin tipa 9 (PCSK9), pri čemu barem jedan od navedena najmanje dva fragmenta sadrže najmanje devet uzastopnih aminokiselinskih ostataka od aminokiselinskih ostataka 153 do 165 od PCSK9 u skladu sa SEQ ID NO:9,1 gdje barem jedan od navedena najmanje dva fragmenta sadrži najmanje devet uzastopnih aminokiselinskih ostataka od aminokiselinskih ostataka 209 do 222 od PCSK9 u skladu sa SEQ ID NO:9.
Nutritional composition according to any one of the preceding embodiments wherein at least 30 wt.% of the palmitic acid is esterified to the sn-2 position of a triglyceride based on total palmitic acid. 
4. Nutritivni pripravak prema bilo kojem od prethodnih zahtjeva gdje je barem 35 tež.% palmitinske kiseline od ukupne palmitinske kiseline esterificirano na sn-2 položaju triglicerida.
a layer (14) for protecting the internal surface of the bed (11), 
- sloj (14) za zaštitu unutarnje površine ležaja (11),
Since the crystals are small, the expansion due to phase transformation will not cause deterioration of the mechanical properties of the cured compound. 
Kako su kristali mali, širenje zbog fazne transformacije neće uzrokovati oštećenje mehaničkih svojstava otvrdnjenog materijala.
Handle (10), in particular of the cremone bolt type, applicable onto the frame (100) of a moveable wing of a window or door and comprising: 
PATENTNI ZAHTJEVI 1. - Kvaka (10), osobito sa zasunom kremonskog tipa, koju se može staviti na okvir (100) pokretnog prozorskog ili vratnog krila i koja sadrži:
wherein Q is a nitrogen atom or a CH group and W is an oxygen or sulfur atom or it is a group NR3 wherein R3 is hydrogen or C1-C4 alkyl; 
[image] pri čemu je Q dušikov atom ili CH skupina, a W je kisik ili atom sumpora ili njegova skupina NR3 pri čemu je R3 vodik ili C1-C4 alkil;
The composition in accordance with claim 1 in powder form, or in the form of pellets, tablets or granules. 
Kompozicija u skladu sa bilo kojim od prethodnih patentnih zahtjeva, u obliku praha ili obliku kuglica, tableta ili granula.
It is also preferred that the water content of the compression mixture is 1.0 to 6.0 %, preferably 1.5 to 5.0 % by weight (determined as loss on drying, at 85°C, 20 minutes, e.g. with a Mettler Toledo HR73 halogen moisture analyser). 
Također je poželjno da sadržaj vode u kompresijskoj smjesi bude 1,0 do 6,0 %, poželjno 1,5 do 5,0 % masenog udjela (određeno kao gubitak tijekom sušenja, na 85 "C, tijekom 20 minuta, na primjer sa Mettler Toledo HR73 halogenim analizatorom vlage).
The receiving method according to claim 9, wherein the remaining bits(s) are MSBs (Most Significant Bits) of the resource allocation information and the defined value is zero. 
Postupak prijenosa prema zahtjevu 9 ili 10, naznačen time da su preostali bit(ovi) MSB-i, NajBitniji Bitovi, podatka o dodjeli resursa, a definirana vrijednost je nula.
treating liquid iron with an initialiser which is a ferrosilicon alloy comprising an effective amount of a Group IIa metal other than magnesium, said Group IIa metal being barium, and said effective amount being sufficient to inactivate the oxygen activity of the liquid iron, 
obrada tekućeg željeza inicijalizatorom koji je ferosilikonska legura koja sadrži učinkovitu količinu barija, ta učinkovita količina je dovoljna za inaktivaciju aktivnosti kisika tekućeg željeza,
represents a wherein * indicates the point of attachment of said group with the rest of the molecule; 
predstavlja [image] pri čemu * označava točku vezanja navedene skupine s ostatkom molekule;
A cellulose fibre based support according to the claim 1, characterized in that the aldehyde function of said organic molecule is in the form of a hemiacetal or acetal. 
Podloga na bazi celuloznih vlakana u skladu s patentnim zahtjevom 1, naznačena time, da je aldehidna funkcionalna skupina navedene organske molekule u obliku poluacetala ili acetala.
This example illustrates suitable formulations for the compounds of this invention, especially the diesters. 
Ovaj primjer ilustrira prikladnu formulaciju za spojeve iz izuma, posebno diestere.
While maintaining the temperature at about 51° C., the reaction was continually stirred and sampled periodically for HPLC. 
Dok je održavana temperatura pri oko 51>C, reakcijska smjesa je bila kontinuirano miješana i periodički su uzimani uzorci za HPLC.
characterized in that, in step (i), the temperature during the addition, optionally dropwise, of the chlorinating agent is -20°C to 5°C and the reaction temperature after the addition, optionally dropwise, of the chlorinating agent is -20°C to 5°C. 
[image] naznačen time što je u koraku (i) temperatura za vrijeme dodavanja sredstva za kloriranje -20°C do 5°C i reakcijska temperatura nakon dodavanja sredstva za kloriranje je -20°C do 5°C.
(S1) adding the at least one organic component (c) to a water-containing solution to form a suspension; 
(SI) dodavanje najmanje jedne organske komponente (c) u otopinu koja sadrži vodu da se dobije suspenzija;
The final blend thus obtained was compressed into 230 mg average weight tablets on a tablet compression machine using 8.73 mm (11/32 inch) round flat-faced beveled edged punches. 
Konačna mješavina koja je dobivena na taj način komprimirana je u tablete prosječne težine od 230 mg na stroju za kompresiju tableta rabeći 8,73 mm (11/32 inča) okrugle plosnato-suočene udarače kosih rubova.
reaction of C with phenyl fluorenyl bromide to create compound 3, or with benzyl bromide to create compound 3 *. 
reakciju C s fenil fluorenil bromidom kako bi se dobio spoj 3 ili s benzil bromidom kako bi se dobio spoj 3*. [image]
The turbid yellow solution is cooled down to 0° and a solution of 5.3 ml DICI in 15 ml THF added within 10 minutes. 
Mutna žuta otopina se ohladi na 0 *C i tijekom 10 minuta se dodaje otopina 5,3 ml DICI u 15 ml THF.
Three new formulations based on sucrose as bulking agent were used for further stability studies. 
Tri nova oblika na bazi saharoze kao sredstva za punjenje korišteni su za dalje studije stabilnosti.
the drain water is caused to flow in a first direction and the fresh water is caused to flow in a second direction; and the first direction is substantially opposite to the second direction. 
drenažna voda protječe u prvom smjeru i svježa voda protječe u drugom smjeru; i prvi smjer je u biti suprotan drugom smjeru. Postupak prema zahtjevu 1 gdje:
If the dosage form according to the invention comprises at least 2 of components (c) and (d) or (f), these may each be present in the same or different subunits (Y). 
Ukoliko oblik davanja prema izumu ima barem 2 od komponenata (c) i (d), odnosno (f), mogu se ove nalaziti u istim ili u različitim podjedinicama (Y).
shoulders of the person when the person is lying on it sideways so that the shape of the spine of the person in this position corresponds as much as possible to the shape of the spine when the person is standing upright; 
određivanje ciljnih vrijednosti za optimalnu kompresijsku udaljenost u zonama ramena, struka i kuka koje ukazuju na to koliko madrac (1) mora biti stisnut u zonama ramena, struka i kuka, tako da kralježnica osobe koja leži bočno na madracu ima isti oblik kao kad stoji u uspravnom položaju;
where R4b is as previously defined. 
(XI) gdje Ra, jest kao što je prethodno definirano.
The hybrid antenna of claim 11, wherein the carbon nanotubes are single-wall carbon nanotubes. The hybrid antenna of claim 11, wherein the conductive composite layer is deposited on the metallic antenna underbody through a technique selected from the group consisting of dip coating, spin coating, printing, spray depositing, and combinations thereof. 
Antena ili hibridna antena prema bilo kojem od zahtjeva 1 - 7, pri čemu se provodni kompozitni sloj deponira tehnikom koja je izabrana iz grupe koja se sastoji od deponiranja slojeva umakanjem, deponiranja slojeva na rotirajuću podlogu djelovanjem centrifugalne sile, metoda štampe, deponiranja slojeva raspršivanjem, i njihovih kombinacija.
The method of claim 1, wherein the peptide is conjugated to keyhole limpet haemocyanin (KLH) or mannan. 
Peptid u skladu s patentnim zahtjevom 1 ili 2, pri čemu je navedeni peptid dio fuzijskog proteina.
wherein R8a, R8b, R8c, R8d are defined as hereinbefore and hereinafter, and then the resulting adduct, is reacted, preferably in situ, with water or an alcohol R′—OH, while R′ denotes optionally substituted C1-4-alkyl, in the presence of an acid, such as for example methanesulphonic acid, sulphuric acid, hydrochloric acid, acetic acid or ammonium chloride, and optionally the product obtained in the reaction with water wherein R′ denotes H is converted, in a subsequent reaction, with an acylating agent, such as for example the corresponding acid chloride or anhydride, into the product of formula II wherein R′ denotes (C1-18-alkyl)carbonyl, (C1-18-alkyl)oxycarbonyl, arylcarbonyl or aryl-(C1-3-alkyl)-carbonyl, which may be substituted as specified. 
pe Hal Tj =X Vi gdje su R" R2 R" R" ovdje prethodno definirani, i tada dobiveni prinos reagira s vodom ili alkoholom R'-OH, gdje R* označava opcijski supstituirani C, _,-alkil, u prisutnosti kiseline te opcijski, proizvod dobiven u reakciji s vodom, gdje R' označava H, pretvara se u naknadnoj reakciji s acilacijskim sredstvom u proizvod formule IL gdje R' označava (C, _,-alkil)karbonil, (C,,,- alkiloksikarbonil, arilkarbonil ili aril-(C, -alkil)-karbonil, koji mogu biti supstituirani kako je naznačeno.
The proteins of the disclosure have a number of different specific uses. 
01.12.2005. Broj objave europske prijave patenta: EP 1742966 A2
is selected from hydrogen, cyano, cyclopropyl, difluoromethyl, halo, hydroxymethyl, methoxy, methyl, trifluoromethoxy, trifluoromethyl, and a five-membered aromatic ring containing one, two, or three heteroatoms selected from nitrogen, oxygen, and sulfur; 
R? je odabrano od vodik, cijano, ciklopropil, difluorometil, halo, hidroksimetil, metoksi, metil, trifluorometoksi, trifluorometil, i peteročlani aromatični prsten koji sadrži jedan, dva, ili tri heteroatoma odabrana od dušika, kisika, i sumpora;
● are administered concomitantly with said conditioned medium or adherent cells and/or 
pri čemu se adherentne stanice kultiviraju do najmanje 60% konfluencije; i/ili
The isolated fusion protein of any one of claims 5-9, wherein the biologically active protein has at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or 100% sequence identity to a coagulation factor selected from the group consisting of factor IX (SEQ ID NOS:1735-1746), factor Vlla, or factor VII (SEQ ID NO:1747). 
Izolirani fuzijski protein prema jednom od zahtjeva 5 do 9, naznačen time, da biološki aktivan protein ima najmanje 95%, ili najmanje 96%, ili najmanje 97%, ili najmanje 98%, ili najmanje 99% ili 100% identiteta sekvence prema faktoru koagulacije odabranom iz skupine koja se sastoji od faktora IX (SEQ ID NO: 1735-1746), faktora VIlIa, ili faktora VII (SEQ ID NO: 1747).